SPPS vs. Recombinant Expression for Peptide Synthesis: Which Method Produces Better Peptides?

Technical Comparison | 2026-07-09 | 11 min read

A 2026 technical comparison of SPPS vs. recombinant expression for peptide synthesis: manufacturing principles, product quality, cost drivers, scalability, and when to choose each method.

Two manufacturing platforms, one goal

Peptide manufacturing has two primary platforms: Solid Phase Peptide Synthesis (SPPS) and recombinant expression. Each has distinct principles, strengths, and limitations. Understanding the technical basis for choosing between them is essential for researchers selecting a peptide supplier and for anyone evaluating COA quality.

SPPS dominates pharmaceutical and research peptide manufacturing. Recombinant expression is used for longer peptides, protein fragments, and some industrial enzymes. The boundary between the two methods is not fixed — it shifts with advances in both technologies.

SPPS: principles and process

Solid Phase Peptide Synthesis builds peptides sequentially on a resin support:

  • **Resin preparation** — the C-terminal amino acid is attached to a solid resin
  • **Fmoc deprotection** — the Fmoc (9-fluorenylmethoxycarbonyl) protecting group is removed with piperidine
  • **Coupling** — the next Fmoc-protected amino acid is activated and coupled to the growing chain
  • **Washing** — unreacted reagents are washed away
  • **Repeat** — steps 2-4 repeat until the full sequence is assembled
  • **Cleavage** — the peptide is released from the resin with TFA, removing side-chain protecting groups
  • **Purification** — RP-HPLC separates the target peptide from truncation and deletion sequences

Fmoc-protected SPPS is the dominant method for most pharmaceutical and research peptides. It handles non-natural amino acids, D-amino acids, and N-methylated residues — modifications that recombinant expression cannot easily accommodate.

Recombinant expression: principles and process

Recombinant expression uses living cells as peptide factories:

  • **Gene design** — the peptide sequence is encoded in a plasmid vector
  • **Cell transformation** — the plasmid is introduced into a host cell (E. coli, Pichia pastoris, or CHO cells)
  • **Expression** — the cell's machinery produces the peptide as part of a fusion protein
  • **Harvest** — cells are lysed; the fusion protein is isolated
  • **Cleavage** — a proteolytic site (e.g., Factor Xa, thrombin) or chemical cleavage releases the target peptide
  • **Purification** — chromatography separates the target from host cell proteins and residual fusion partner

E. coli is the most common host for research peptides. Pichia pastoris (yeast) offers better secretion and post-translational modifications. CHO cells are used for therapeutic proteins requiring mammalian glycosylation.

Direct comparison: SPPS vs. recombinant expression

| Criterion | SPPS | Recombinant Expression | | --- | --- | --- | | Typical sequence length | 3-50 amino acids | 30-500 amino acids | | Non-natural amino acids | Yes, easily incorporated | Limited | | D-amino acids | Yes | No | | N-methylation | Yes | No | | PEGylation site-specific | Yes | Yes (genetic code expansion) | | Glycosylation | Limited | Possible (mammalian cells) | | Typical purity (crude) | 40-70% | 20-60% | | Typical purity (purified) | 95-99%+ | 90-98% | | Endotoxin risk | Low (chemical synthesis) | High (E. coli) | | Host cell proteins | None | Significant (requires removal) | | Cost (short peptides) | Low | Higher | | Cost (long peptides) | High | Lower | | Scalability | Moderate (batch size limited) | High (fermentation scales) |

When to choose SPPS

SPPS is the right choice when:

  • **Sequence length is below 50 amino acids** — SPPS purity advantage is largest for shorter sequences
  • **Non-natural amino acids are required** — Aib, D-amino acids, N-methylated residues are straightforward in SPPS
  • **Site-specific modifications are needed** — fatty acid chains, fluorescent tags, or PEG can be incorporated at defined positions
  • **Endotoxin-free material is required** — SPPS eliminates host cell protein contamination
  • **Regulatory documentation is important** — SPPS processes are easier to characterize and document

Most GLP-1 analogs (tirzepatide, semaglutide, mazdutide, survodutide) are manufactured by SPPS because they require non-natural amino acids and site-specific fatty acid conjugation.

When to choose recombinant expression

Recombinant expression is the right choice when:

  • **Sequence length exceeds 50 amino acids** — SPPS crude purity drops significantly above 50 residues; recombinant is more efficient
  • **Large quantities are needed** — fermentation scales more cost-effectively than batch SPPS for multi-gram quantities
  • **Glycosylation or other PTMs are needed** — mammalian cell expression provides authentic post-translational modifications
  • **Cost is the primary driver for long sequences** — recombinant becomes cost-competitive above 50-60 amino acids

Long peptide hormones (insulin analogs, growth hormone fragments) are often manufactured recombinantly for cost reasons even when SPPS is technically feasible.

Hybrid approaches: the convergence

Modern peptide manufacturing increasingly uses hybrid approaches:

  • **Native chemical ligation (NCL)** — combines SPPS-synthesized fragments with recombinant expression of other fragments, ligated chemically
  • **Sortase-mediated ligation** — uses enzyme-catalyzed ligation between SPPS and recombinant fragments
  • **Solid-phase fragment assembly** — SPPS synthesizes 30-50 residue fragments that are then ligated

These approaches capture the purity advantage of SPPS for each fragment while achieving cost efficiency for long sequences through recombinant fragment production.

Implications for COA evaluation

When evaluating a COA, the manufacturing method determines what risks to look for:

  • **SPPS peptides** — look for truncation sequences, deletion sequences, and racemization artifacts. MS verification of the correct mass is sufficient for identity.
  • **Recombinant peptides** — look for host cell protein residuals, endotoxin, proteolytic clips, and residual fusion partner. Endotoxin testing is essential; MS alone is insufficient.

A COA from a recombinant peptide should include endotoxin testing (LAL or rFC), host cell protein assay, and residual DNA. A COA from SPPS should include MS verification of the correct mass and HPLC purity with chromatogram.

How ZePeptide manufactures peptides

ZePeptide uses SPPS as the primary manufacturing platform for all sequences below 50 amino acids. Non-natural amino acids, D-amino acids, N-methylated residues, and site-specific modifications are standard capabilities. Recombinant expression is available through a qualified manufacturing partner for longer sequences or large-quantity requirements.

Every COA includes HPLC purity, MS verification, endotoxin testing, and residual solvent panel, regardless of manufacturing platform.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides